Leap Therapeutics in reverse merger | Chemical & Engineering News
Volume 94 Issue 35 | p. 18 | Concentrates
Issue Date: September 5, 2016

Leap Therapeutics in reverse merger

Department: Business
Keywords: finance, mergers and acquisitions, biopharmaceuticals

Trying to raise capital in a down period for initial public stock offerings, Leap Therapeutics will conduct a reverse merger with publicly held Macrocure. As a result, Leap’s stock will be traded and Macrocure will become a subsidiary. The deal should give Leap $30 million to support development of its immuno-oncology antibodies. A week earlier, the regenerative medicine firm BioCardia agreed to do a reverse merger with Tiger X Medical. And PixarBio, a pain management company cofounded by MIT professor Robert Langer, is in the process of reverse merging with an undisclosed public firm.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment